CSL gets approval in Europe for its new haemophilia treatment

David Silverman/Getty Images

Australian blood products and flu vaccine group CSL has won approval from the European Commission for a new treatment for haemophilia A.

A short time ago, CSL shares were up 1.3% to $103.66.

The treatment, AFSTYLA, will be launched in European markets in the coming months, as market access opens.

“We are very excited to add this treatment to our industry-leading portfolio of coagulation therapies and look forward to the positive impact AFSTYLA can have on haemophilia A patients in the European Union,” says CSL chief scientific officer Andrew Cuthbertson.

Haemophilia A is a congenital disorder whose symptoms include prolonged or spontaneous bleeding.

The top 10 Australian company by market capitalisation last year became the world’s second largest flu vaccine business by buying a loss-making subsidiary of Swiss pharmaceutical multinational Novartis for $US275 million ($A357 million).

CSL in August posted a full year profit of $US1.38 billion, a 6% rise.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.